See the factory by live video walkthrough
Book an on-site factory visit in Guangzhou
Formulating cosmetics for the delicate eye area demands more than a gentle formula—it requires proof that your product won't irritate one of the most sensitive parts of the human body. Ocular tolerance testing is…
Formulating cosmetics for the delicate eye area demands more than a gentle formula—it requires proof that your product won’t irritate one of the most sensitive parts of the human body. Ocular tolerance testing is that proof. Whether you’re launching a new eye cream, mascara, or cleansing balm, knowing when and why to request this testing can mean the difference between a smooth market entry and costly delays.
Ocular tolerance testing evaluates whether a cosmetic product causes irritation or damage to the eye and surrounding tissues. It’s designed to mimic accidental product entry into the eye—a real risk for eye-area cosmetics. The tests assess stinging, redness, swelling, corneal opacity, and other adverse reactions.
Several validated methods exist, ranging from cell-based in vitro assays to clinical patch tests. The choice of method depends on your product type, claims, and target market regulations.
The periorbital skin is four times thinner than the rest of the face, and the tear film can quickly dissolve water-soluble irritants, delivering them directly to the cornea. Regulatory bodies and retailers increasingly expect brands to substantiate “safe for use around eyes” or “ophthalmologist-tested” claims. Without clear evidence, you risk:
Not every product needs a full ophthalmologist-led study. Here’s how to decide based on your situation:
If your product is designed to be applied on or very near the eye—mascara, eyeliner, eye shadow, eye cream, makeup remover, or eyelash adhesive—you should have at least an in vitro eye irritation test. For leave-on products, a clinical eye instillation study provides the strongest defense.
Even a minor adjustment in preservatives, surfactants, or fragrance can alter the irritation profile. If you’ve reformulated an existing product or switched raw material suppliers, request a bridging ocular tolerance study to confirm the safety profile hasn’t shifted.
The EU, UK, and Australia have some of the toughest requirements. The EU’s Scientific Committee on Consumer Safety (SCCS) notes frequently cite the need for eye irritation data in dossiers. If you’re expanding from the US (where such testing is less commonly enforced) to the EU, expect to provide in vitro or clinical data for eye-area products.
Terms like “no tears,” “eyelid-safe,” or “ophthalmologist tested” must be backed by scientifically robust evidence. A human clinical study under ophthalmological control is the standard for such claims. In contrast, a simple “dermatologically tested” claim may not suffice if the product is clearly intended for the eye contour.
Sprays, pump-activated liquids, and powders that can become airborne present a higher risk of accidental eye contact. Any product in these formats should be evaluated even if it isn’t marketed specifically as an eye product—because real-world use often leads to eye exposure.
Aligning with your budget, timeline, and market requirements is essential. The table below summarizes key options:
| Test method | Best for | Regulatory acceptance | Typical timeline |
|---|---|---|---|
| In vitro (e.g., EpiOcular) | Initial screening, rinse-off products, budget-conscious projects | EU, UK, AU; accepted for safety assessment; may not support “no tears” claims alone | 2–3 weeks |
| HET-CAM | Surfactants, shampoos, liquid cleansers; quick classification | Limited; often used as a screen, not a definitive claim support | 1–2 weeks |
| Clinical instillation | Leave-on eye cream, mascara, eyelash serum; strong marketing claims | Globally accepted; gold standard for claims | 6–8 weeks (recruitment + testing + report) |
| Periocular RIPT | Eye-area skincare; to rule out sensitization and irritation | Defacto requirement for leave-on facial products in most markets | 8–10 weeks |
When you work with a contract manufacturer or formulator, be explicit about your needs early. Use these talking points:
It depends on the market. In the EU, a CPSR must demonstrate that eye irritation potential has been assessed for products likely to come into contact with the eyes. While it may not require a specific test name, data must be provided. In the US, FDA does not mandate ocular testing, but failure to substantiate safety can lead to enforcement if complaints arise.
Consumer protection authorities generally expect human data for strong performance claims. An in vitro test can support safety, but to claim “tear-free” or “no stinging,” you’ll need a clinical study with human subjects under ophthalmological supervision.
Yes. Powders can migrate into the tear film and cause mechanical irritation. A periocular patch test plus an in vitro eye irritation assay is a reasonable combo. Additionally, microbial testing becomes even more critical because powders often come into repeated contact with the applicator and eyelid.
You may benefit from read-across data if the formula is near-identical. The safety assessor can use existing data provided the differences in actives, preservatives, or pH are negligible. Always request a formal bridging justification from the toxicologist who signs the CPSR.
Indefinitely, as long as the formula doesn’t change. If you change even one ingredient or supplier, a new assessment is usually required. Keep the study report on file—it’s part of your product information file (PIF) and must be available for inspection.
Eye-area products require extra care, but the investment in the right testing pays off in consumer trust and market access. To discuss your product’s specific needs and get a custom quote, Request a Quote from our team today.
With more than 20 years of experience in OEM/ODM/Private Label Cosmetics, I'd love to share valuable knowledge related to cosmetics & skincare products from a top-tier Chinese supplier's perspective.
